Department of Gastroenterology and Metabolism,
Graduate School of Biomedical & Health Sciences, Hiroshima University
  • TOP >
  • PUBLICATION LIST Principal Achievement

PUBLICATION LIST

Principal Achievement

Principal Achievement

98 papers were published in the journals whose Impact Factors are higher than 7.0 during these 18 years starting CY2000 to CY2017!

Journal nameImpact Factor(2016)

  • New Engl J Med (1報)
    72.406
  • Nat Med (1報)
    29.886
  • Nat Genet (6報)
    27.959
  • J Am Coll Cardiol (8報)
    19.896
  • Circulation (6報)
    19.309
  • Gastroenterology (10報)
    18.392
  • Sci Transl Med (1報)
    16.796
  • Gut (5報)
    16.658
  • Circulation Researce (1報)
    13.965

Journal nameImpact Factor(2016)

  • Nat Rev Gastroenterol Hepatol (1報)
    13.678
  • Hepatology (20報)
    13.246
  • J Clin Invest (1報)
    12.784
  • J Hepatol (19報)
    12.486
  • Nat Commun (2報)
    12.124
  • Clin Cancer Res (5報)
    9.619
  • Am J Gastroenterol (7報)
    9.566
  • Cancer Res (3報)
    9.122
  • J Autoimmun (1報)
    7.641

  • Higashi Y. Sasaki S. Nakagawa K. Matsuura H. Oshima T, and Chayama K, Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med, 2002; 346: 1954-62.

  • Sainz B, Jr.. Barretto N. Martin D N. Hiraga N. Imamura M. Hussain S. Marsh K A. Yu X. Chayama K. Alrefai W A, and Uprichard S L, Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med, 2012; 18: 281-5.
  • Tsuge M. Hamamoto R. Silva F P. Ohnishi Y. Chayama K. Kamatani N. Furukawa Y, and Nakamura Y, A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5' flanking region of SMYD3 is a risk factor for human cancers. Nat Genet, 2005; 37: 1104-7.

  • Kamatani Y. Wattanapokayakit S. Ochi H. Kawaguchi T. Takahashi A. Hosono N. Kubo M. Tsunoda T. Kamatani N. Kumada H. Puseenam A. Sura T. Daigo Y. Chayama K. Chantratita W. Nakamura Y, and Matsuda K, A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet, 2009; 41: 591-5.

  • Miki D. Kubo M. Takahashi A. Yoon K A. Kim J. Lee G K. Zo J I. Lee J S. Hosono N. Morizono T. Tsunoda T. Kamatani N. Chayama K. Takahashi T. Inazawa J. Nakamura Y, and Daigo Y, Variation in TP63 is associated with lung adenocarcinoma susceptibility in Japanese and Korean populations. Nat Genet, 2010; 42: 893-6.

  • Miki D. Ochi H. Hayes C N. Abe H. Yoshima T. Aikata H. Ikeda K. Kumada H. Toyota J. Morizono T. Tsunoda T. Kubo M. Nakamura Y. Kamatani N, and Chayama K, Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. Nat Genet, 2011; 43: 797-800.

  • Fujimoto A. Totoki Y. Abe T. Boroevich K A. Hosoda F. Nguyen H H. Aoki M. Hosono N. Kubo M. Miya F. Arai Y. Takahashi H. Shirakihara T. Nagasaki M. Shibuya T. Nakano K. Watanabe-Makino K. Tanaka H. Nakamura H. Kusuda J. Ojima H. Shimada K. Okusaka T. Ueno M. Shigekawa Y. Kawakami Y. Arihiro K. Ohdan H. Gotoh K. Ishikawa O. Ariizumi S. Yamamoto M. Yamada T. Chayama K. Kosuge T. Yamaue H. Kamatani N. Miyano S. Nakagama H. Nakamura Y. Tsunoda T. Shibata T, and Nakagawa H, Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet, 2012; 44: 760-4.

  • Fujimoto A, Furuta M, Totoki Y, Tsunoda T, Kato M, Shiraishi Y, Tanaka H, Taniguchi H, Kawakami Y, Ueno M, Gotoh K, Ariizumi S, Wardell CP, Hayami S, Nakamura T, Aikata H, Arihiro K, Boroevich KA, Abe T, Nakano K, Maejima K, Sasaki-Oku A, Ohsawa A, Shibuya T, Nakamura H, Hama N, Hosoda F, Arai Y, Ohashi S, Urushidate T, Nagae G, Yamamoto S, Ueda H, Tatsuno K, Ojima H, Hiraoka N, Okusaka T, Kubo M, Marubashi S, Yamada T, Hirano S, Yamamoto M, Ohdan H, Shimada K, Ishikawa O, Yamaue H, Chayama K, Miyano S, Aburatani H, Shibata T, Nakagawa H. Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. Nat Genet. 2016; 48: 500-9.

  • Higashi Y. Sasaki S. Nakagawa K. Ueda T. Yoshimizu A. Kurisu S. Matsuura H. Kajiyama G, and Oshima T, A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: a multicenter study. J Am Coll Cardiol, 2000; 35: 284-91.

  • Sanada M. Higashi Y. Nakagawa K. Sasaki S. Kodama I. Tsuda M. Nagai N, and Ohama K, Relationship between the angiotensin-converting enzyme genotype and the forearm vasodilator response to estrogen replacement therapy in postmenopausal women. J Am Coll Cardiol, 2001; 37: 1529-35.

  • Higashi Y. Sasaki S. Nakagawa K. Matsuura H. Kajiyama G, and Oshima T, Effect of the angiotensin-converting enzyme inhibitor imidapril on reactive hyperemia in patients with essential hypertension: relationship between treatment periods and resistance artery endothelial function. J Am Coll Cardiol, 2001; 37: 863-70.

  • Higashi Y. Nakagawa K. Kimura M. Noma K. Hara K. Sasaki S. Goto C. Oshima T. Chayama K, and Yoshizumi M, Circadian variation of blood pressure and endothelial function in patients with essential hypertension:a comparison of dippers and non-dippers. J Am Coll Cardiol, 2002; 40: 2039-43.

  • Higashi Y. Sasaki S. Nakagawa K. Kimura M. Noma K. Hara K. Matsuura H. Goto C. Oshima T. Chayama K, and Yoshizumi M, Low body mass index is a risk factor for impaired endothelium-dependent vasodilation in humans: role of nitric oxide and oxidative stress. J Am Coll Cardiol, 2003; 42: 256-63.

  • Nakano Y. Niida S. Dote K. Takenaka S. Hirao H. Miura F. Ishida M. Shingu T. Sueda T. Yoshizumi M, and Chayama K, Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation. J Am Coll Cardiol, 2004; 43: 818-25.

  • Oshima T. Ozono R. Yano Y. Oishi Y. Teragawa H. Higashi Y. Yoshizumi M, and Kambe M, Association of Helicobacter pylori infection with systemic inflammation and endothelial dysfunction in healthy male subjects. J Am Coll Cardiol, 2005; 45: 1219-22.

  • Noma K. Goto C. Nishioka K. Jitsuiki D. Umemura T. Ueda K. Kimura M. Nakagawa K. Oshima T. Chayama K. Yoshizumi M. Liao J K, and Higashi Y, Roles of rho-associated kinase and oxidative stress in the pathogenesis of aortic stiffness. J Am Coll Cardiol, 2007; 49: 698-705.

  • Higashi Y1, Sasaki S, Kurisu S, Yoshimizu A, Sasaki N, Matsuura H, Kajiyama G, Oshima T. Regular aerobic exercise augments endothelium-dependent vascular relaxation in normotensive as well as hypertensive subjects: role of endothelium-derived nitric oxide. Circulation, 2000; 100: 1194-202.

  • Higashi Y S S, Kurisu S, Yoshimizu A, Sasaki N, Matsuura H, Kajiyama G., Exercise and endothelial function. Circulation, 2000; 102: e179.

  • Goto C. Higashi Y. Kimura M. Noma K. Hara K. Nakagawa K. Kawamura M. Chayama K. Yoshizumi M, and Nara I, Effect of different intensities of exercise on endothelium-dependent vasodilation in humans: role of endothelium-dependent nitric oxide and oxidative stress. Circulation, 2003; 108: 530-5.

  • Higashi Y. Kimura M. Hara K. Noma K. Jitsuiki D. Nakagawa K. Oshima T. Chayama K. Sueda T. Goto C. Matsubara H. Murohara T, and Yoshizumi M, Autologous bone-marrow mononuclear cell implantation improves endothelium-dependent vasodilation in patients with limb ischemia. Circulation, 2004; 109: 1215-8.

  • Fujii Y. Nishioka K. Yoshizumi M. Chayama K, and Higashi Y, Images in cardiovascular medicine. Corkscrew collaterals in thromboangitis obliterans (Buerger's disease). Circulation, 2007; 116: e539-40.

  • Maruhashi T. Soga J. Fujimura N. Idei N. Mikami S. Iwamoto Y. Kajikawa M. Matsumoto T. Kihara Y. Chayama K. Noma K. Nakashima A. Tomiyama H. Takase B. Yamashina A, and Higashi Y, Hyperbilirubinemia, augmentation of endothelial function, and decrease in oxidative stress in Gilbert syndrome. Circulation, 2012; 126: 598-603.

  • Imamura M. Ogawa T. Sasaguri Y. Chayama K, and Ueno H, Suppression of macrophage infiltration inhibits activation of hepatic stellate cells and liver fibrogenesis in rats. Gastroenterology, 2005; 128: 138-46.

  • Soetikno R. Friedland S. Kaltenbach T. Chayama K, and Tanaka S, Nonpolypoid (flat and depressed) colorectal neoplasms. Gastroenterology, 2006; 130: 566-76; quiz 588-9.

  • Yamamoto H. Kitadai Y. Yamamoto H. Oue N. Ohdan H. Yasui W, and Kikuchi A, Laminin gamma2 mediates Wnt5a-induced invasion of gastric cancer cells. Gastroenterology, 2009; 137: 242-52, 252.e1-6.

  • Matsumura T. Hu Z. Kato T. Dreux M. Zhang Y Y. Imamura M. Hiraga N. Juteau J M. Cosset F L. Chayama K. Vaillant A, and Liang T J, Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry. Gastroenterology, 2009; 137: 673-81.

  • Tsukada H. Ochi H. Maekawa T. Abe H. Fujimoto Y. Tsuge M. Takahashi H. Kumada H. Kamatani N. Nakamura Y, and Chayama K, A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C. Gastroenterology, 2009; 136: 1796-805 e6.

  • Ochi H. Maekawa T. Abe H. Hayashida Y. Nakano R. Kubo M. Tsunoda T. Hayes C N. Kumada H. Nakamura Y, and Chayama K, ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients. Gastroenterology, 2010; 139: 1190-7.

  • Wakita T. Suzuki T. Evans M J. Shimotohno K. Chayama K. Matsuura Y. Hijikata M. Moriishi K. Seya T. Enomoto N. Koike K. Kato N. Kanto T, and Hotta H, Will there be an HCV meeting in 2020? Summary of the 17th international meeting on hepatitis C virus and related viruses. Gastroenterology, 2011; 141: e1-5.

  • Hewett D G. Kaltenbach T. Sano Y. Tanaka S. Saunders B P. Ponchon T. Soetikno R, and Rex D K, Validation of a simple classification system for endoscopic diagnosis of small colorectal polyps using narrow-band imaging. Gastroenterology, 2012; 143: 599-607 e1.

  • Abe Y. Aly H H. Hiraga N. Imamura M. Wakita T. Shimotohno K. Chayama K, and Hijikata M, Thromboxane A2 synthase inhibitors prevent production of infectious hepatitis C virus in mice with humanized livers. Gastroenterology, 2013; 145: 658-67 e11.

  • Soetikno R. Subramanian V. Kaltenbach T. Rouse R V. Sanduleanu S. Suzuki N. Tanaka S, and McQuaid K, The detection of nonpolypoid (flat and depressed) colorectal neoplasms in patients with inflammatory bowel disease. Gastroenterology, 2013; 144: 1349-52, 1352 e1-6.

  • He S, Lin B, Chu V, Hu Z, Hu X, Xiao J, Wang AQ, Schweitzer CJ, Li Q, Imamura M, Hiraga N, Southall N, Ferrer M, Zheng W, Chayama K, Marugan JJ, Liang TJ. Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection. Sci Transl Med. 2015; 7: 282ra249.

  • Hayes C N. Kobayashi M. Akuta N. Suzuki F. Kumada H. Abe H. Miki D. Imamura M. Ochi H. Kamatani N. Nakamura Y, and Chayama K, HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut, 2011; 60: 261-7.

  • Nakamura S. Sugiyama T. Matsumoto T. Iijima K. Ono S. Tajika M. Tari A. Kitadai Y. Matsumoto H. Nagaya T. Kamoshida T. Watanabe N. Chiba T. Origasa H. Asaka M, and Group J G S, Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut, 2012; 61: 507-13.

  • Shi N. Hiraga N. Imamura M. Hayes C N. Zhang Y. Kosaka K. Okazaki A. Murakami E. Tsuge M. Abe H. Aikata H. Takahashi S. Ochi H. Tateno-Mukaidani C. Yoshizato K. Matsui H. Kanai A. Inaba T. McPhee F. Gao M, and Chayama K, Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice. Gut, 2013; 62: 1055-61.

  • Ishikawa H MM, Suzuki S, Tokudome S, Saida Y, Abe T, Okamura S, Tajika M, Joh T, Tanaka S, Kudo SE, Matsuda T, Iimuro M, Yukawa T, Takayama T, Sato Y, Lee K, Kitamura S, Mizuno M, Sano Y, Gondo N, Sugimoto K, Kusunoki M, Goto C, Matsuura N, Sakai T, Wakabayashi K. The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial. Gut. 2014; 63: 1755-1759.

  • Van Renne N, Roca Suarez AA, Duong FH, Gondeau C, Calabrese D, Fontaine N, Ababsa A, Bandiera S, Croonenborghs T, Pochet N, De Blasi V, Pessaux P, Piardi T, Sommacale D, Ono A, Chayama K, Fujita M, Nakagawa H, Hoshida Y, Zeisel MB, Heim MH, Baumert TF, Lupberger J. miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis. Gut. 2017; in press.

  • Ishida M. Ishida T. Nakashima H. Miho N. Miyagawa K. Chayama K. Oshima T. Kambe M, and Yoshizumi M, Mnk1 is required for angiotensin II-induced protein synthesis in vascular smooth muscle cells. Circ Res, 2003; 93: 1218-24.

  • Hayes C N. Imamura M. Aikata H, and Chayama K, Genetics of IL28B and HCV--response to infection and treatment. Nat Rev Gastroenterol Hepatol, 2012; 9: 406-417.

  • Chayama K. Suzuki F. Tsubota A. Kobayashi M. Arase Y. Saitoh S. Suzuki Y. Murashima N. Ikeda K. Takahashi N. Kinoshita M, and Kumada H, Association of amino acid sequence in the PKR-eIF2 phosphorylation homology domain and response to interferon therapy. Hepatology, 2000; 32: 1138-44.

  • Ikeda K. Arase Y. Saitoh S. Kobayashi M. Suzuki Y. Suzuki F. Tsubota A. Chayama K. Murashima N, and Kumada H, Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology, 2000; 32: 228-32.

  • Tsuge M. Hiraga N. Takaishi H. Noguchi C. Oga H. Imamura M. Takahashi S. Iwao E. Fujimoto Y. Ochi H. Chayama K. Tateno C, and Yoshizato K, Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus. Hepatology, 2005; 42: 1046-54.

  • Noguchi C. Ishino H. Tsuge M. Fujimoto Y. Imamura M. Takahashi S, and Chayama K, G to A hypermutation of hepatitis B virus. Hepatology, 2005; 41: 626-33.

  • Hatakeyama T. Noguchi C. Hiraga N. Mori N. Tsuge M. Imamura M. Takahashi S. Kawakami Y. Fujimoto Y. Ochi H. Abe H. Maekawa T. Kawakami H. Yatsuji H. Aisaka Y. Kohno H. Aimitsu S, and Chayama K, Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine. Hepatology, 2007; 45: 1179-86.

  • Utoh R. Tateno C. Yamasaki C. Hiraga N. Kataoka M. Shimada T. Chayama K, and Yoshizato K, Susceptibility of chimeric mice with livers repopulated by serially subcultured human hepatocytes to hepatitis B virus. Hepatology, 2008; 47: 435-46.

  • Akuta N. Suzuki F. Hirakawa M. Kawamura Y. Yatsuji H. Sezaki H. Suzuki Y. Hosaka T. Kobayashi M. Kobayashi M. Saitoh S. Arase Y. Ikeda K. Chayama K. Nakamura Y, and Kumada H, Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology, 2010; 52: 421-9.

  • Hiraga N. Imamura M. Abe H. Hayes C N. Kono T. Onishi M. Tsuge M. Takahashi S. Ochi H. Iwao E. Kamiya N. Yamada I. Tateno C. Yoshizato K. Matsui H. Kanai A. Inaba T. Tanaka S, and Chayama K, Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo. Hepatology, 2011; 54: 781-8.

  • Hiraga N. Abe H. Imamura M. Tsuge M. Takahashi S. Hayes C N. Ochi H. Tateno C. Yoshizato K. Nakamura Y. Kamatani N, and Chayama K, Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus. Hepatology, 2011; 54: 764-71.

  • Saeed M. Shiina M. Date T. Akazawa D. Watanabe N. Murayama A. Suzuki T. Watanabe H. Hiraga N. Imamura M. Chayama K. Choi Y. Krawczynski K. Liang T J. Wakita T, and Kato T, In vivo adaptation of hepatitis C virus in chimpanzees for efficient virus production and evasion of apoptosis. Hepatology, 2011; 54: 425-33.

  • Ohishi W. Fujiwara S. Cologne J B. Suzuki G. Akahoshi M. Nishi N. Tsuge M, and Chayama K, Impact of radiation and hepatitis virus infection on risk of hepatocellular carcinoma. Hepatology, 2011; 53: 1237-45.

  • Suzuki F. Suzuki Y. Akuta N. Sezaki H. Hirakawa M. Kawamura Y. Hosaka T. Kobayashi M. Saito S. Arase Y. Ikeda K. Kobayashi M. Chayama K. Kamatani N. Nakamura Y. Miyakawa Y, and Kumada H, Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology, 2011; 53: 415-21.

  • Okazaki A. Hiraga N. Imamura M. Hayes C N. Tsuge M. Takahashi S. Aikata H. Abe H. Miki D. Ochi H. Tateno C. Yoshizato K. Ohdan H, and Chayama K, Severe necroinflammatory reaction caused by natural killer cell-mediated Fas/Fas ligand interaction and dendritic cells in human hepatocyte chimeric mouse. Hepatology, 2012; 56: 555-66.

  • Chayama K. Takahashi S. Toyota J. Karino Y. Ikeda K. Ishikawa H. Watanabe H. McPhee F. Hughes E, and Kumada H, Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology, 2012; 55: 742-8.

  • Abe H, Hayes CN, Chayama K. New insight into the enhanced effect of pegylated interferon-alpha. Hepatology. 2014; 60: 1435-1437.

  • Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, Kawakami Y, Ido A, Yamamoto K, Takaguchi K, Izumi N, Koike K, Takehara T, Kawada N, Sata M, Miyagoshi H, Eley T, McPhee F, Damokosh A, Ishikawa H, Hughes E. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014; 59: 2083-2091.

  • Chayama K, Notsumata K, Kurosaki M, Sato K, Rodrigues L, Jr., Setze C, Badri P, Pilot-Matias T, Vilchez RA, Kumada H. Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients. Hepatology. 2015; 61: 1523-1532.

  • Kamada Y, Ono M, Hyogo H, Fujii H, Sumida Y, Mori K, Tanaka S, Yamada M, Akita M, Mizutani K, Fujii H, Yamamoto A, Takamatsu S, Yoshida Y, Itoh Y, Kawada N, Chayama K, Saibara T, Takehara T, Miyoshi E. A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers. Hepatology. 2015; 62: 1433-1443.

  • Kumada H, Chayama K, Rodrigues L, Jr., Suzuki F, Ikeda K, Toyoda H, Sato K, Karino Y, Matsuzaki Y, Kioka K, Setze C, Pilot-Matias T, Patwardhan M, Vilchez RA, Burroughs M, Redman R. Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology. 2015; 62: 1037-1046.

  • Abe-Chayama H, Hayes CN, Chayama K. Pan-genotypic cell culture system for propagation of hepatitis C virus clinical isolates. Hepatology. 2016; 64: 1356-8.

  • Ohira M. Ishiyama K. Tanaka Y. Doskali M. Igarashi Y. Tashiro H. Hiraga N. Imamura M. Sakamoto N. Asahara T. Chayama K, and Ohdan H, Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice. J Clin Invest, 2009; 119: 3226-35.

  • Tanaka Y. Hanada K. Orito E. Akahane Y. Chayama K. Yoshizawa H. Sata M. Ohta N. Miyakawa Y. Gojobori T, and Mizokami M, Molecular evolutionary analyses implicate injection treatment for schistosomiasis in the initial hepatitis C epidemics in Japan. J Hepatol, 2005; 42: 47-53.

  • Hiraga N. Imamura M. Hatakeyama T. Kitamura S. Mitsui F. Tanaka S. Tsuge M. Takahashi S. Abe H. Maekawa T. Ochi H. Tateno C. Yoshizato K. Wakita T, and Chayama K, Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice. J Hepatol, 2009; 51: 1046-54.

  • Nabeshima Y. Tazuma S. Kanno K. Hyogo H, and Chayama K, Deletion of angiotensin II type I receptor reduces hepatic steatosis. J Hepatol, 2009; 50: 1226-35.

  • Abe H. Ochi H. Maekawa T. Hayes C N. Tsuge M. Miki D. Mitsui F. Hiraga N. Imamura M. Takahashi S. Ohishi W. Arihiro K. Kubo M. Nakamura Y, and Chayama K, Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol, 2010; 53: 439-43.

  • Yokosuka O. Takaguchi K. Fujioka S. Shindo M. Chayama K. Kobashi H. Hayashi N. Sato C. Kiyosawa K. Tanikawa K. Ishikawa H. Masaki N. Seriu T, and Omata M, Long-term use of entecavir in nucleoside-naive Japanese patients with chronic hepatitis B infection. J Hepatol, 2010; 52: 791-9.

  • Abe H. Imamura M. Hiraga N. Tsuge M. Mitsui F. Kawaoka T. Takahashi S. Ochi H. Maekawa T. Hayes C N. Tateno C. Yoshizato K. Murakami S. Yamashita N. Matsuhira T. Asai K, and Chayama K, ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo. J Hepatol, 2011; 55: 11-18.

  • Abe H. Hayes C N. Ochi H. Maekawa T. Tsuge M. Miki D. Mitsui F. Hiraga N. Imamura M. Takahashi S. Kubo M. Nakamura Y, and Chayama K, IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. J Hepatol, 2011; 54: 1094-101.

  • Ohara E. Hiraga N. Imamura M. Iwao E. Kamiya N. Yamada I. Kono T. Onishi M. Hirata D. Mitsui F. Kawaoka T. Tsuge M. Takahashi S. Abe H. Hayes C N. Ochi H. Tateno C. Yoshizato K. Tanaka S, and Chayama K, Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice. J Hepatol, 2011; 54: 872-8.

  • Kawaoka T. Hayes C N. Ohishi W. Ochi H. Maekawa T. Abe H. Tsuge M. Mitsui F. Hiraga N. Imamura M. Takahashi S. Kubo M. Tsunoda T. Nakamura Y. Kumada H, and Chayama K, Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. J Hepatol, 2011; 54: 408-14.

  • Fujimoto Y, Ochi H, Maekawa T, Abe H, Hayes CN, Kumada H, Nakamura Y, Chayama K. A single nucleotide polymorphism in activated Cdc42 associated tyrosine kinase 1 influences the interferon therapy in hepatitis C patients. J Hepatol. 2011; 54: 629-39.

  • Ono A. Suzuki F. Kawamura Y. Sezaki H. Hosaka T. Akuta N. Kobayashi M. Suzuki Y. Saitou S. Arase Y. Ikeda K. Kobayashi M. Watahiki S. Mineta R, and Kumada H, Long-term continuous entecavir therapy in nucleos(t)ide-naive chronic hepatitis B patients. J Hepatol, 2012; 57: 508-14.

  • Kumada H. Toyota J. Okanoue T. Chayama K. Tsubouchi H, and Hayashi N, Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol, 2012; 56: 78-84.

  • Urabe Y. Ochi H. Kato N. Kumar V. Takahashi A. Muroyama R. Hosono N. Otsuka M. Tateishi R. Lo P H. Tanikawa C. Omata M. Koike K. Miki D. Abe H. Kamatani N. Toyota J. Kumada H. Kubo M. Chayama K. Nakamura Y, and Matsuda K, A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region. J Hepatol, 2013; 58: 875-82.

  • Suzuki Y. Ikeda K. Suzuki F. Toyota J. Karino Y. Chayama K. Kawakami Y. Ishikawa H. Watanabe H. Hu W. Eley T. McPhee F. Hughes E, and Kumada H, Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol, 2013; 58: 655-62.

  • Karino Y. Toyota J. Ikeda K. Suzuki F. Chayama K. Kawakami Y. Ishikawa H. Watanabe H. Hernandez D. Yu F. McPhee F, and Kumada H, Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol, 2013; 58: 646-54.

  • Akamatsu S, Hayes CN, Ochi H, Uchida T, Kan H, Murakami E, Abe H, Tsuge M, Miki D, Akiyama R, Hiraga N, Imamura M, Aikata H, Kawaoka T, Kawakami Y, Chayama K. Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A. J Hepatol. 2015; 63: 554-563.

  • Yamamoto N, Sato Y, Munakata T, Kakuni M, Tateno C, Sanada T, Hirata Y, Murakami S, Tanaka Y, Chayama K, Hatakeyama H, Hyodo M, Harashima H, Kohara M. Novel pH-sensitive multifunctional envelope-type nanodevice for siRNA-based treatments for chronic HBV infection. J Hepatol. 2016; 64: 547-55.

  • Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Ledinghen V, Kumar M, Lupsor-Platon M, Han KH, Cardoso AC, Ferraioli G, Chan WK, Wong VW, Myers RP, Chayama K, Friedrich-Rust M, Beaugrand M, Shen F, Hiriart JB, Sarin SK, Badea R, Jung KS, Marcellin P, Filice C, Mahadeva S, Wong GL, Crotty P, Masaki K, Bojunga J, Bedossa P, Keim V, Wiegand J. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017; 66: 1022-1030.

  • Furuta M, Ueno M, Fujimoto A, Hayami S, Yasukawa S, Kojima F, Arihiro K, Kawakami Y, Wardell CP, Shiraishi Y, Tanaka H, Nakano K, Maejima K, Sasaki-Oku A, Tokunaga N, Boroevich KA, Abe T, Aikata H, Ohdan H, Gotoh K, Kubo M, Tsunoda T, Miyano S, Chayama K, Yamaue H, Nakagawa H. Whole genome sequencing discriminates hepatocellular carcinoma with intrahepatic metastasis from multi-centric tumors. J Hepatol. 2017; 66: 363-373.

  • Fujimoto A, Furuta M, Shiraishi Y, Gotoh K, Kawakami Y, Arihiro K, Nakamura T, Ueno M, Ariizumi S, Nguyen HH, Shigemizu D, Abe T, Boroevich KA, Nakano K, Sasaki A, Kitada R, Maejima K, Yamamoto Y, Tanaka H, Shibuya T, Shibata T, Ojima H, Shimada K, Hayami S, Shigekawa Y, Aikata H, Ohdan H, Marubashi S, Yamada T, Kubo M, Hirano S, Ishikawa O, Yamamoto M, Yamaue H, Chayama K, Miyano S, Tsunoda T, Nakagawa H. Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity. Nat Commun. 2015; 6: 6120.

  • Aizawa S, Okamoto T, Sugiyama Y, Kouwaki T, Ito A, Suzuki T, Ono C, Fukuhara T, Yamamoto M, Okochi M, Hiraga N, Imamura M, Chayama K, Suzuki R, Shoji I, Moriishi K, Moriya K, Koike K, Matsuura Y. TRC8-dependent degradation of hepatitis C virus immature core protein regulates viral propagation and pathogenesis. Nat Commun. 2016; 7: 11379.

  • Kitadai Y. Haruma K. Mukaida N. Ohmoto Y. Matsutani N. Yasui W. Yamamoto S. Sumii K. Kajiyama G. Fidler I J, and Tahara E, Regulation of disease-progression genes in human gastric carcinoma cells by interleukin 8. Clin Cancer Res, 2000; 6: 2735-40.

  • Kuniyasu H. Ohmori H. Sasaki T. Sasahira T. Yoshida K. Kitadai Y, and Fidler I J, Production of interleukin 15 by human colon cancer cells is associated with induction of mucosal hyperplasia, angiogenesis, and metastasis. Clin Cancer Res, 2003; 9: 4802-10.

  • Kuroda T. Kitadai Y. Tanaka S. Yang X. Mukaida N. Yoshihara M, and Chayama K, Monocyte chemoattractant protein-1 transfection induces angiogenesis and tumorigenesis of gastric carcinoma in nude mice via macrophage recruitment. Clin Cancer Res, 2005; 11: 7629-36.

  • Kodama M. Kitadai Y. Tanaka M. Kuwai T. Tanaka S. Oue N. Yasui W, and Chayama K, Vascular endothelial growth factor C stimulates progression of human gastric cancer via both autocrine and paracrine mechanisms. Clin Cancer Res, 2008; 14: 7205-14.

  • Hirata D. Yamabuki T. Miki D. Ito T. Tsuchiya E. Fujita M. Hosokawa M. Chayama K. Nakamura Y, and Daigo Y, Involvement of epithelial cell transforming sequence-2 oncoantigen in lung and esophageal cancer progression. Clin Cancer Res, 2009; 15: 256-66.

  • Locke C R, 3rd. Talley N J. Nelson D K. Haruma K. Weaver A L. Zinsmeister A R, and Melton L J, 3rd, Helicobacter pylori and dyspepsia: a population-based study of the organism and host. Am J Gastroenterol, 2000; 95: 1906-13.

  • Tsubota A. Arase Y. Saitoh S. Kobayashi M. Suzuki Y. Suzuki F. Chayama K. Murashima N. Ikeda K, and Kumada H, Lamivudine therapy for spontaneously occurring severe acute exacerbation in chronic hepatitis B virus infection: a preliminary study. Am J Gastroenterol, 2001; 96: 557-62.

  • Sasao S. Hiyama T. Tanaka S. Mukai S. Yoshihara M, and Chayama K, Medical malpractice litigation in gastroenterological practice in Japan: a 22-yr review of civil court cases. Am J Gastroenterol, 2006; 101: 1951-3.

  • Hiyama T. Yoshihara M. Tanaka S, and Chayama K, Trend in Japanese malpractice litigation involving gastrointestinal endoscopy. Am J Gastroenterol, 2009; 104: 251-2.

  • Hiyama T. Yoshihara M. Tanaka S, and Chayama K, Change in malpractice claims in Japanese gastroenterological practice. Am J Gastroenterol, 2012; 107: 143-4.

  • Abe H. Hayes C N. Hiraga N. Imamura M. Tsuge M. Miki D. Takahashi S. Ochi H, and Chayama K, A translational study of resistance emergence using sequential direct-acting antiviral agents for hepatitis C using ultra-deep sequencing. Am J Gastroenterol, 2013; 108: 1464-72.

  • Oka S, Tanaka S, Saito Y, Iishi H, Kudo SE, Ikematsu H, Igarashi M, Saitoh Y, Inoue Y, Kobayashi K, Hisabe T, Tsuruta O, Sano Y, Yamano H, Shimizu S, Yahagi N, Watanabe T, Nakamura H, Fujii T, Ishikawa H, Sugihara K. Local recurrence after endoscopic resection for large colorectal neoplasia: a multicenter prospective study in Japan. Am J Gastroenterol. 2015; 110: 697-707.

  • Yokoi K. Sasaki T. Bucana C D. Fan D. Baker C H. Kitadai Y. Kuwai T. Abbruzzese J L, and Fidler I J, Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. Cancer Res, 2005; 65: 10371-80.

  • Yang L. Avila H. Wang H. Trevino J. Gallick G E. Kitadai Y. Sasaki T, and Boyd D D, Plasticity in urokinase-type plasminogen activator receptor (uPAR) display in colon cancer yields metastable subpopulations oscillating in cell surface uPAR density--implications in tumor progression. Cancer Res, 2006; 66: 7957-67.

  • Nakamura T. Kuwai T. Kitadai Y. Sasaki T. Fan D. Coombes K R. Kim S J, and Fidler I J, Zonal heterogeneity for gene expression in human pancreatic carcinoma. Cancer Res, 2007; 67: 7597-604.

  • Aisaka Y. Watanabe Y. Kamiyasu M. Masanaga T. Tsuji K. Nakanishi T. Kajiyama G, and Gershwin M E, Immune-mediated cholangiohepatitis in neonatally thymectomized mice: the role of T cells and analysis of T-cell receptor Vbeta usage. J Autoimmun, 2000; 14: 239-46.